(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 March 2008 (06.03.2008)

PCT

(10) International Publication Number
WO 2008/027523 A3

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:
PCT/US2007/019152

(22) International Filing Date: 30 August 2007 (30.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/841,177	30 August 2006 (30.08.2006)	US
60/954,466	7 August 2007 (07.08.2007)	US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GULLAPALLI, Rampurna** [US/US]; c/o Novartis Vaccines And Diagnostics Inc, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **HASHASH, Ahmad** [US/US]; c/o Novartis Vaccines And Diagnostics Inc, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **KARPINSKI, Piotr, H.** [US/US]; c/o Novartis, One Health Plaza 104/3, East Hanover, NJ 07936-1080 (US). **LIN, Kangwen, L.** [US/US]; c/o Novartis Vaccines And Diagnostics Inc, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **LOESER, Eric, M.** [US/US]; c/o Novartis, One Health Plaza 104/3, East Hanover, NJ 07936-1080 (US). **OKHAMAFE, Augustus, O.** [US/US]; c/o Novartis Vaccines And Diagnostics Inc, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **SUTTON, Paul, Allen** [US/US]; c/o Novartis, One Health Plaza 104/3, East Honover, NJ 07936-1080 (US). **SY, Eduardo** [US/US]; c/o Novartis Vaccines And Diagnostics Inc., P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(74) Agents: **ABRAHAMSON, Susan, L.** et al.; Novartis Vaccines & Diagnostics Inc, Intellectual Property R338, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
10 April 2008

(54) Title: SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF

(57) Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of { 1 -methyl-5- [2-(5-trifluoromethyl- 1 H-imidazol-2-yl)-pyridin-4-yloxy] - 1 H-benzoimidazol-2-yl } -(4- trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.

WO 2008/027523 A3